Nutrition 21, LLC Announces The Presentation Of Proteomic Results Of A Nitrosigine® Clinical Study At The Renowned Experimental Biology 2015 Annual Meeting

NUTRITION 21, LLC ANNOUNCES THE PRESENTATION OF PROTEOMIC RESULTS OF A NITROSIGINE® CLINICAL STUDY AT THE RENOWNED EXPERIMENTAL BIOLOGY 2015 ANNUAL MEETING

PURCHASE, N.Y. March 30, 2015 – Nutrition 21, LLC, a fully owned subsidiary of JDS Therapeutics, LLC, is proud to announce the presentation of new clinical study results supporting the efficacy of Nitrosigine® bonded arginine silicate (ASI), titled, “Arginine Silicate Supplementation Decreases Markers of Cardiovascular, Renal and Metabolic Dysfunction and Increases Markers of Vasodilation and Cardiovascular Health in Healthy Adult Males.” The study will be presented today to scientists and other professionals at the acclaimed Experimental Biology 2015 annual meeting and the abstract will be published in the Federation of American Societies for Experimental Biology Journal (FASEB). The demonstrated connections between Nitrosigine® bonded arginine silicate supplementation and various protein levels contributes to the understanding of the ingredient’s mechanism of action. 

Read the full press release here – Results Of A Nitrosigine® Clinical Study

To find out more about Nitrosigine, visit http://www.Nitrosigine.com